Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have unique features of fighting cancers.
| Website | https://www.ymmuno.bio |
| Employees | 8 (2 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology Research |
| Keywords | Immuno-Oncology, Oncology Therapeutics, Clinical Stage Oncology, Cancer Research, Immunotherapy Research, Pharmaceutical Research, Biopharmaceutical Development, New Cancer Therapies, Antibody Engineering, Novel Cancer Treatments, Biotechnology, Antibody Drug Conjugates, Drug Development, Cancer Drug Discovery, Cancer Treatment, Therapeutic Antibodies, Solid Tumor Therapy |
| Competitors | Roche, GSK, Bristol Myers Squibb, Amgen, Regeneron, Genmab, Receptos, a wholly-owned subsidiary of Celgene, MedImmune, AbCellera, Adimab +39 more (view full list) |
Looking for a particular Ymmunobio employee's phone or email?
Ymmunobio Questions
Christian Germa is the CFO of Ymmunobio.
2 people are employed at Ymmunobio.
Top Ymmunobio Employees
-
Christian Germa
Chief Financial Officer at Ymmunobio
New Jersey, United States11
Related Companies
G2Crowd Trusted
300K+
Plugin Users
